Africa not ‘walking away’ from AstraZeneca vaccine, says disease control body

The African Union’s disease control body said on Thursday that it was not “walking away” from AstraZeneca’s COVID-19 vaccine, after trial data
showed it had greatly reduced efficacy against the coronavirus variant dominant in South Africa.

African countries are due to receive 100 million doses of the AstraZeneca shot this year under an AU vaccine plan.

For more coronavirus news, visit our dedicated page.

Africa CDC Director John Nkengasong told a news conference that more work needed to be done to understand how the vaccine worked against the more contagious 501Y.V2 variant first identified in South Africa late last year.

For all the latest headlines follow our Google News channel online or via the app

South Africa has paused the rollout of AstraZeneca shots to health workers and said on Wednesday it could seek to sell or swap doses of the vaccine.

John Nkengasong, Africa’s Director of Centers for Disease Control (CDC), speaks during a news conference at the African Union Headquarters in Addis Ababa, Ethiopia. (Reuters)

Nkengasong added that six countries other than South Africa had reported the presence of the variant. This has alarmed health experts who have raised concerns about its ability to potentially evade the immune response generated by prior exposure to the coronavirus or vaccines.

The six countries are Botswana, Comoros, Ghana, Kenya, Mozambique and Zambia.

“For countries that have not reported the circulation of the 501Y.V2 variant, we recommend that they proceed with the rollout of the AstraZeneca vaccine,” Nkengasong said.

“For countries that have reported the circulation of the 501Y.V2 variant, we recommend the acceleration of their preparedness to introduce all vaccines that have received emergency use authorization or approval by regulatory authorities. Consideration should be given to the effectiveness of the vaccine against the 501Y.V2 variant.”

Nkengasong said the Africa CDC would be doing its own evaluations of the AstraZeneca vaccine across multiple countries and that no countries had said they would not be using the vaccine.

He added that the AU was in talks with Johnson & Johnson on the supply of more COVID-19 vaccines, beyond the 120 million doses that already feature in its vaccine plan.

Separately, Kenya said it would move ahead with plans to use the AstraZeneca vaccine.

Read more:

South Africa suspends AstraZeneca COVID-19 vaccine drive

AstraZeneca vaccine being tweaked to fight S. Africa variant

What we know about the South African coronavirus variant